Lipophagy impairment is associated with disease progression in NAFLD
While their model can be a great fit for those with premium insurance coverage, it can become an insurmountable financial burden for many others
Many patients do beautifully at doses that would be considered subtherapeutic by weight loss clinic standards
Key published studies include: Teichman et al., 2006 (JCEM): Dose-dependent GH and IGF-1 elevation with CJC-1295 DAC in healthy adults Raun et al., 1998 (Eur J Endocrinol): Ipamorelin demonstrated selective GH release without cortisol/prolactin elevation Johansen et al., 1999: Phase I/II Ipamorelin trial showed dose-response relationship with no significant adverse effects Bowers et al., 2004: Foundational research on GHRH/GHRP synergistic GH release mechanisms Neither CJC-1295 nor Ipamorelin has completed Phase 3 clinical trials

These studies assessed the efficacy and safety of escalating weekly doses of tirzepatide from 5 mg to 15 mg over 12 weeks compared to placebo,188 and over 26 weeks compared to placebo or dulaglutide, selective GLP-1RAs.189 Subsequently, tirzepatide has been extensively investigated in the SURPASS program, a comprehensive development initiative targeting T2DM that is inadequately controlled by various glucose-lowering regimens, including lifestyle alone (SURPASS-1),190 metformin monotherapy (SURPASS-2),191 metformin with or without sodium-glucose co-transporter 2 inhibitors (SGLT2i) (SURPASS-3),192 combination therapy including metformin, SGLT2i, and sulfonylureas (SURPASS-4),193 insulin glargine with or without metformin (SURPASS-5),88 and insulin lispro with basal insulin (SURPASS-6).194 Across all SURPASS trials, tirzepatide demonstrated a dose-dependent reduction in HbA1c levels, which consistently exceeded the reductions observed with comparator treatments

Irrespective of the size of the case, our goal is to give every client the time and attention they deserve and get justice for all